Shared on29 Jul 25Fair value Decreased 15%
CureVac's analyst price target was revised downward, primarily reflecting a modest improvement in future P/E while profitability remained stable, resulting in a new target of $5.35. What's in the News BioNTech SE has agreed to acquire CureVac N.V. in a stock-for-stock deal, valuing CureVac at approximately $1.25 billion.